Sidebar Home Right
Photostream
-
INA-PROACTIVE Study
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
-
PEER-Peppes Study
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
-
ORCHID Study
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
-
D2EFT Study
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
-
ICOS Study
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
-
ITAC Study
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
-
InVITE Study
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
-
AFIRE Study
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
-
Sepsis Study
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
-
TRIPOD Study
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
Our Studies
Our Studies
-
INA-PROACTIVE Study
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
-
PEER-Peppes Study
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
-
ORCHID Study
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
-
D2EFT Study
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
-
ICOS Study
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
-
ITAC Study
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
-
InVITE Study
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
-
AFIRE Study
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
-
Sepsis Study
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
-
TRIPOD Study
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
© Copyright - Ina-Respond. 2022
Most Commented